With survival rates in ovarian carcinoma depending largely on sustained response to platinum based therapies, primarily carboplatin, we sought to determine if CLPTM1L contributes to platinum resistance in a therapeutically targetable manner. The gene discussed is CLPTM1L; the disease is ovarian carcinoma.